James Shaw

Professor James Shaw is a leading academic at Newcastle University specializing in diabetes research with extensive contributions to hypoglycemia management, islet transplantation, and cystic fibrosis-related diabetes. His work bridges clinical practice and molecular research, focusing on innovative interventions for diabetes complications and glucose monitoring technologies.

• Primary Affiliation: Faculty of Medical Sciences, Newcastle University
• Research Leadership: Principal investigator for multiple clinical trials including HypoCOMPaSS and PHT2
• Collaborations: Works with international consortia on islet transplantation and diabetes technology assessment

Shaw's research centers on diabetes pathophysiology with particular emphasis on hypoglycemia awareness mechanisms, pancreatic islet function, and cystic fibrosis-related metabolic complications. His laboratory investigates molecular pathways involving ER stress, oxidative damage, and CFTR modulation in diabetes development. Clinically, he pioneers psycho-educational interventions for hypoglycemia prevention and develops novel monitoring protocols using continuous glucose monitoring systems. His work frequently addresses real-world challenges in diabetes management across diverse patient populations including children, elderly, and transplant recipients.

Recent publications demonstrate a clear trajectory toward digital health solutions for diabetes self-management, molecular characterization of diabetes subtypes, and optimization of transplantation outcomes. His research integrates patient-reported outcomes with physiological metrics to create holistic diabetes care frameworks. Shaw's team has significantly advanced understanding of hypoglycemia symptomatology and awareness restoration through structured interventions.

• Principal Investigator: HypoCOMPaSS trial (hypoglycemia awareness restoration)
• Principal Investigator: PHT2 trial (hypoglycemia prevention in type 2 diabetes)
• Co-investigator: SIGNET trial (organ donation optimization)

Shaw mentors numerous early-career researchers and clinicians, fostering expertise in diabetes clinical trials methodology and translational research. His team receives substantial funding from major UK research councils and diabetes charities for investigator-led trials and mechanistic studies. Current projects focus on exercise physiology in diabetes, digital therapeutics for hypoglycemia prevention, and molecular diagnostics for cystic fibrosis-related diabetes.